FDA approval of expanded approval for expanded Exparel label to include two additional nerve block indications – Pacira Biosciences
Pacira BioSciences, Inc. announced that the FDA has approved its supplemental new drug application (sNDA) to expand the Exparel (bupivacaine liposome injectable suspension) label to include administration in… read more.